Tactile Medical Announces Publication of Phase 2 Study Results for PressureSafe™ Device

BTIG Maintains Buy Rating on Tactile Systems Technology, Lowers Price Target

BTIG has maintained its 'Buy' rating on Tactile Systems Technology, Inc. while adjusting its price target from $35 to $31.

Tactile Systems Technology, Inc. Reports Third Quarter 2026 Financial Results and Business Updates

Tactile Medical reported Q3 2026 revenue of $91.9 million, raised its full-year Adjusted EBITDA outlook, and announced several operational and regulatory milestones.

Tactile Systems: 3 Key Takeaways for Long-Term Investors

Tactile Systems raised full-year adjusted EBITDA guidance to $50-52 million, driven by 13% year-over-year growth in lymphedema product revenue to $81.8 million and operational improvements that reduced medical record review times by 50%. The company is absorbing temporary inventory delays in its airway clearance business through margin expansion and controlled spending, while positioning itself for sustained growth through expanded sales teams and AI-enabled order management systems.

Tactile Medical's Spending Outpaces Sales: Rapid Earnings Reaction

Tactile Systems Technology reported Q3 revenue growth of 7% to $91.9 million, but net income declined to $7.2 million from $8.2 million as operating expenses grew at the same pace as sales. While the core lymphedema business grew 13%, the smaller airway clearance line contracted 25% due to inventory adjustments from a product launch. The company maintained its 2026 revenue guidance but slightly raised profit forecasts, though Q4 adjusted EBITDA is expected to be 2-10% below last year.

BTIG Maintains Buy on Tactile Systems Tech, Lowers Price Target to $35

BTIG analyst Ryan Zimmerman maintains Tactile Systems Tech (NASDAQ:TCMD) with a Buy and lowers the price target from $39 to $35.

Tactile Systems Technology shares are trading lower after the company reported Q2 financial results. The company narrowed its FY26 sales guidance.